LLY

1,145.52

-0.3%↓

JNJ

239.29

+1.3%↑

ABBV

225.65

-0.38%↓

UNH

407.9

-0.49%↓

MRK

117.62

-1.96%↓

LLY

1,145.52

-0.3%↓

JNJ

239.29

+1.3%↑

ABBV

225.65

-0.38%↓

UNH

407.9

-0.49%↓

MRK

117.62

-1.96%↓

LLY

1,145.52

-0.3%↓

JNJ

239.29

+1.3%↑

ABBV

225.65

-0.38%↓

UNH

407.9

-0.49%↓

MRK

117.62

-1.96%↓

LLY

1,145.52

-0.3%↓

JNJ

239.29

+1.3%↑

ABBV

225.65

-0.38%↓

UNH

407.9

-0.49%↓

MRK

117.62

-1.96%↓

LLY

1,145.52

-0.3%↓

JNJ

239.29

+1.3%↑

ABBV

225.65

-0.38%↓

UNH

407.9

-0.49%↓

MRK

117.62

-1.96%↓

Accueil・Liste d'Actions・Lantheus Holdings Inc

Lantheus Holdings Inc

Ouvert

SecteurSoins de santé

101.58 2.59

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

97.75

Max

102.37

Chiffres clés
By Trading Economics
Revenu	64M 118M
Ventes	-29M 377M
P/E Moyenne du Secteur	23.181 49.888
BPA	1.46
Marge bénéficiaire	31.383
Employés	1,193
EBITDA	-17M 81M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+5.99% upside

Dividendes
By Dow Jones
Prochains Résultats	5 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	609M 6.3B
Ouverture précédente	98.99
Clôture précédente	101.58

Sentiment de l'Actualité

By Acuity

50%

153 / 344 Classement par Healthcare

Lantheus Holdings Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 juin 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 juin 2026, 23:45 UTC

Acquisitions, Fusions, Rachats

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 juin 2026, 23:44 UTC

Acquisitions, Fusions, Rachats

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 juin 2026, 23:44 UTC

Acquisitions, Fusions, Rachats

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 juin 2026, 23:43 UTC

Acquisitions, Fusions, Rachats

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 juin 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 juin 2026, 22:06 UTC

Acquisitions, Fusions, Rachats

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 juin 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 juin 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 juin 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 juin 2026, 20:51 UTC

Résultats

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 juin 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juin 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 juin 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9 juin 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 juin 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 juin 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 juin 2026, 18:52 UTC

Acquisitions, Fusions, Rachats

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 juin 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 juin 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9 juin 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 juin 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 juin 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 juin 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 juin 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 juin 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juin 2026, 16:20 UTC

Market Talk

Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

9 juin 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 juin 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparaison

Variation de prix

Lantheus Holdings Inc prévision

Objectif de Prix

By TipRanks

5.99% hausse

Prévisions sur 12 Mois

Moyen 106 USD 5.99%

Haut 115 USD

Bas 94 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

9 ratings

Achat

Maintien

Vente

Basé sur 9 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

153 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.